Company Description
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.
It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.
The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada.
The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018.
The company was founded in 2016 and is based in Littleton, Colorado.
| Country | United States |
| Founded | 2016 |
| IPO Date | Dec 11, 2020 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 270 |
| CEO | R. Huntsman |
Contact Details
Address: 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 United States | |
| Phone | 866 908 4867 |
| Website | vivos.com |
Stock Details
| Ticker Symbol | VVOS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 1716166 |
| CUSIP Number | 92859E207 |
| ISIN Number | US92859E2072 |
| Employer ID | 81-3224056 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| R. Kirk Huntsman | Co-Founder, Chairman of the Board and Chief Executive Officer |
| Todd Huntsman | Co-Founder and Senior Vice President of Product and Technology |
| RaeAnn Byrnes | Co-Founder and Senior Vice President of Events and Clinical Advisory Services |
| Susan McCullough | Co-Founder and Executive Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 11, 2026 | 8-K | Current Report |
| Aug 11, 2026 | SCHEDULE 13G | Filing |
| Aug 3, 2026 | 8-K | Current Report |
| Jul 15, 2026 | SCHEDULE 13D | Filing |
| Jul 7, 2026 | 8-K | Current Report |
| Jun 25, 2026 | 8-K | Current Report |
| Jun 16, 2026 | 8-K | Current Report |
| Jun 16, 2026 | 8-K | Current Report |
| Jun 8, 2026 | 8-K | Current Report |
| May 20, 2026 | 10-Q | Quarterly Report |